Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells
出版年份 2014 全文链接
标题
Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells
作者
关键词
Ibrutinib, ErbB2, Breast cancer, BEZ235 and tyrosine kinase inhibitor
出版物
INVESTIGATIONAL NEW DRUGS
Volume 32, Issue 6, Pages 1096-1104
出版商
Springer Nature
发表日期
2014-07-31
DOI
10.1007/s10637-014-0141-2
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
- (2014) Carlos L. Arteaga et al. CANCER CELL
- AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2+ breast tumor cells from Balb-neuT mice
- (2014) Nicole Grabinski et al. CELLULAR SIGNALLING
- High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cells
- (2014) Lesley A. Mathews Griner et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
- (2013) J. Ferlay et al. EUROPEAN JOURNAL OF CANCER
- Brutonˈs tyrosine kinase-an integral protein of B cell development that also has an essential role in the innate immune system
- (2013) Gabriela López-Herrera et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Tyrosine Kinase BMX Phosphorylates Phosphotyrosine-Primed Motif Mediating the Activation of Multiple Receptor Tyrosine Kinases
- (2013) S. Chen et al. Science Signaling
- Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
- (2013) A. O. Walter et al. Cancer Discovery
- Ibrutinib (PCI-32765), the First BTK (Bruton’s Tyrosine Kinase) Inhibitor in Clinical Trials
- (2013) Jennifer R. Brown Current Hematologic Malignancy Reports
- Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer
- (2012) Caterina Carmi et al. BIOCHEMICAL PHARMACOLOGY
- Bruton Tyrosine Kinase (BTK) and Its Role in B-cell Malignancy
- (2012) Joseph J. Buggy et al. INTERNATIONAL REVIEWS OF IMMUNOLOGY
- Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells
- (2012) Nicole Grabinski et al. Molecular Cancer
- Cysteine Mapping in Conformationally Distinct Kinase Nucleotide Binding Sites: Application to the Design of Selective Covalent Inhibitors
- (2011) Emeline Leproult et al. JOURNAL OF MEDICINAL CHEMISTRY
- Chemical genetic strategy for targeting protein kinases based on covalent complementarity
- (2011) A. L. Garske et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
- (2009) Wenjun Zhou et al. NATURE
- Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase
- (2008) Wooyoung Hur et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance
- (2008) Grazia Arpino et al. ENDOCRINE REVIEWS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started